This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bradshaw-Pierce, E. L. Articles by Gustafson, D. L. Search for Related Content PubMed Articles by Bradshaw-Pierce, E. L. Articles by Gustafson, D. L.

A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man

Authors' Affiliations: ¹ Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado and ² Division of Medical Oncology, School of Medicine, University of Colorado Health Sciences Center, Aurora, Colorado

Requests for reprints: Daniel L. Gustafson, Animal Control Center, VTH, Room ACC208, Colorado State University, 300 W. Drake Road Fort Collins, CO 80523-1620. Phone: 970-297-1278; Fax: 970-297-1254; E-mail: Daniel.Gustafson{at}ColoState.edu.

Purpose: Docetaxel (Taxotere), an important chemotherapeutic agent with shown activity in a broad range of cancers, is being investigated for use in combination therapies and as an antiangiogenic agent. Docetaxel exhibits a complex pharmacologic profile with high interpatient variability. Pharmacokinetic models capable of predicting exposure under various dosing regimens would aid the rational development of clinical protocols.

Experimental Design: A pharmacokinetic study of docetaxel at 5 and 20 mg/kg was carried out in female BALB/c mice. Tissues were collected at various time points and analyzed by liquid chromatography-tandem mass spectrometry. Time course tissue distribution and pharmacokinetic data were used to build and validate a physiologically based pharmacokinetic (PBPK) model in mice. Specific and nonspecific tissue partitioning, metabolism, and elimination data were coupled with mouse physiologic variables to develop a PBPK model that describes docetaxel plasma and tissue pharmacokinetic. The PBPK model was then modified with human model variables to predict the plasma distribution of docetaxel.

Results: Resulting simulation data were compared with actual measured data obtained from our pharmacokinetic study (mouse), or from published data (human), using pharmacokinetic variables calculated using compartmental or noncompartmental analysis to assess model predictability.

Conclusions: The murine PBPK model developed can accurately predict plasma and tissue levels at the 5 and 20 mg/kg doses. The human PBPK model is capable of estimating plasma levels at 30, 36, and 100 mg/m². This will enable us to develop and test various dosing regimens (e.g., metronomic schedules and combination therapies) to achieve specific tissue and plasma concentrations to maximize therapeutic benefit while minimizing toxicity.

This article has been cited by other articles:

				A. Coxon, T. Bush, D. Saffran, S. Kaufman, B. Belmontes, K. Rex, P. Hughes, S. Caenepeel, J. B. Rottman, A. Tasker, et al. Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors Clin. Cancer Res., January 1, 2009; 15(1): 110 - 118. [Abstract] [Full Text] [PDF]

				E. L. Bradshaw-Pierce, C. A. Steinhauer, D. Raben, and D. L. Gustafson Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma Mol. Cancer Ther., September 1, 2008; 7(9): 3006 - 3017. [Abstract] [Full Text] [PDF]

				A. A.M. van der Veldt, A. A. Lammertsma, and N. H. Hendrikse [11C]Docetaxel and Positron Emission Tomography for Noninvasive Measurements of Docetaxel Kinetics Clin. Cancer Res., December 15, 2007; 13(24): 7522 - 7522. [Full Text] [PDF]

				D. L. Gustafson, S. G. Eckhardt, and E. L. Bradshaw-Pierce Clin. Cancer Res., December 15, 2007; 13(24): 7522 - 7522. [Full Text] [PDF]